GGrantIndex
← Leaderboards

Todd W Vanderah

University Of Arizona

$11,756,178
Attributed
$18,534,109
Total exposure
12
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.4M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$24,860,391 · 12
CDC$350,000 · 1

By mechanism

R01$8,369,218 · 4
P30$6,676,282 · 1
U01$5,906,221 · 1
P01$2,350,058 · 2
T32$859,118 · 1
K02$477,232 · 1

Most similar at University Of Arizona

Same institution · by research overlap

Others in their field

Top investigators on “Pain

Research focus

PainOpioidAnimalsAgonistDosePreventBehavioralChronic PainCellsMorphineDesignEndocannabinoidsBiochemicalReportingMechanicsAddictionInflammatoryRewardsIn VivoMediatingBaseRattusAcuteReceptor

Grant awards (53)

PNA5: A Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Vascular Dementia and Alzheimer's Disease Related Dementia: an FDA required Toxicology Study$1,990,623
U01 · FY2025 · AG
The Center of Excellence in Addiction Studies (CEAS)$1,346,821
P30 · FY2025 · DA
Endocannabinoid Targeting for Opioid Induced Respiratory Depression$541,993
R01 · FY2025 · DA
Expanding access to MOUD for patients in the emergency department: research and coordination$350,000
U48 · FY2025 · DP
Interdisciplinary Training of Future Physician Scientists$175,635
T32 · FY2025 · GM · contact PI
PNA5: A Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Vascular Dementia and Alzheimer's Disease Related Dementia: an FDA required Toxicology Study$1,707,517
U01 · FY2024 · AG
The Center of Excellence in Addiction Studies (CEAS)$1,346,821
P30 · FY2024 · DA
Interdisciplinary Training of Future Physician Scientists$179,808
T32 · FY2024 · GM · contact PI
PNA5: A Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Vascular Dementia and Alzheimer's Disease Related Dementia: an FDA required Toxicology Study$2,208,081
U01 · FY2023 · AG
The Center of Excellence in Addiction Studies (CEAS)$1,346,821
P30 · FY2023 · DA
Interdisciplinary Training of Future Physician Scientists$171,278
T32 · FY2023 · GM · contact PI
Endocannabinoid Targeting for Opioid Induced Respiratory Depression$1,648,561
R01 · FY2022 · DA
The Center of Excellence in Addiction Studies (CEAS)$1,346,821
P30 · FY2022 · DA
Interdisciplinary Training of Future Physician Scientists$171,108
T32 · FY2022 · GM · contact PI
The Center of Excellence in Addiction Studies (CEAS)$1,288,998
P30 · FY2021 · DA
Cannabinoid CB2 Agonists for Treatment of Breast Cancer Induced Bone Pain$337,106
R01 · FY2021 · CA · contact PI
Interdisciplinary Training of Future Physician Scientists$161,289
T32 · FY2021 · GM · contact PI
New Modalities for the Treatment of Pain and Drug Abuse-Biochemical Core$117,622
P01 · FY2021 · DA · contact PI
2020 APSA West Regional Meeting$12,300
R13 · FY2021 · GM · contact PI
Role of opioid-induced S1P/S1PR1 axis activation in neuroinflammatory reponses$565,658
R01 · FY2020 · DA
Cannabinoid CB2 Agonists for Treatment of Breast Cancer Induced Bone Pain$337,106
R01 · FY2020 · CA · contact PI
New Modalities for the Treatment of Pain and Drug Abuse-Biochemical Core$117,622
P01 · FY2020 · DA · contact PI
Role of opioid-induced S1P/S1PR1 axis activation in neuroinflammatory reponses$565,658
R01 · FY2019 · DA
Cannabinoid CB2 Agonists for Treatment of Breast Cancer Induced Bone Pain$326,992
R01 · FY2019 · CA · contact PI
New Modalities for the Treatment of Pain and Drug Abuse-Biochemical Core$195,849
P01 · FY2019 · DA · contact PI
Role of opioid-induced S1P/S1PR1 axis activation in neuroinflammatory reponses$591,350
R01 · FY2018 · DA
Cannabinoid CB2 Agonists for Treatment of Breast Cancer Induced Bone Pain$337,106
R01 · FY2018 · CA · contact PI
New Modalities for the Treatment of Pain and Drug Abuse-Biochemical Core$117,622
P01 · FY2018 · DA · contact PI
Cannabinoid CB2 Agonists for Treatment of Breast Cancer Induced Bone Pain$350,481
R01 · FY2017 · CA · contact PI
New Modalities for the Treatment of Pain and Drug Abuse-Biochemical Core$117,622
P01 · FY2017 · DA · contact PI
Cannabinoid CB2 Agonists for Treatment of Breast Cancer-Induced Bone Pain$292,581
R01 · FY2014 · CA · contact PI
Cathepsin Inhibitors for Treatment of Breast Cancer Induced Bone Pain$209,962
R41 · FY2014 · CA
Cannabinoid CB2 Agonists for Treatment of Breast Cancer-Induced Bone Pain$52,884
R01 · FY2014 · CA · contact PI
BIOCHEMICAL CORE$324,115
P01 · FY2013 · DA · contact PI
Cannabinoid CB2 Agonists for Treatment of Breast Cancer-Induced Bone Pain$283,652
R01 · FY2013 · CA · contact PI
Cannabinoid CB2 Agonists for Treatment of Breast Cancer-Induced Bone Pain$45,433
R01 · FY2013 · CA · contact PI
BIOCHEMICAL CORE$332,166
P01 · FY2012 · DA · contact PI
Cannabinoid CB2 Agonists for Treatment of Breast Cancer-Induced Bone Pain$301,879
R01 · FY2012 · CA · contact PI
BIOCHEMICAL CORE$332,369
P01 · FY2011 · DA · contact PI
Cannabinoid CB2 Agonists for Treatment of Breast Cancer-Induced Bone Pain$301,996
R01 · FY2011 · CA · contact PI
BIOCHEMICAL CORE$369,099
P01 · FY2010 · DA · contact PI
Cannabinoid CB2 Agonists for Treatment of Breast Cancer-Induced Bone Pain$311,116
R01 · FY2010 · CA · contact PI
BIOCHEMICAL CORE$325,972
P01 · FY2009 · DA · contact PI
Brain Stem Mechanisms of Opioid Induced Pain$101,248
K02 · FY2009 · DA · contact PI
Brain Stem Mechanisms of Opioid Induced Pain$98,297
K02 · FY2008 · DA · contact PI
Brain Stem Mechanisms of Opioid Induced Pain$95,434
K02 · FY2007 · DA · contact PI
RVM CCK, Pain, and Opioid Tolerance$184,925
R01 · FY2006 · DA · contact PI
Brain Stem Mechanisms of Opioid Induced Pain$92,654
K02 · FY2006 · DA · contact PI
RVM CCK, Pain, and Opioid Tolerance$178,546
R01 · FY2005 · DA
Brain Stem Mechanisms of Opioid Induced Pain$89,599
K02 · FY2005 · DA
RVM CCK, Pain, and Opioid Tolerance$265,125
R01 · FY2004 · DA
RVM CCK, Pain, and Opioid Tolerance$265,125
R01 · FY2003 · DA
RVM CCK, Pain, and Opioid Tolerance$283,945
R01 · FY2002 · DA